HIV Viral Suppression Status and Associated Factors of Dolutegravir based regimen among Children and Adolescents receiving ART
DOI:
https://doi.org/10.69614/ejrh.v18i02.963Keywords:
Anti-retroviral, dolutegravir, viral load, children, adolescents , EthiopiaAbstract
Background:
Anti-Retroviral Treatment (ART) reduces morbidity and mortality, promotes normal growth and development, and improves the quality of life for children and adolescents living with HIV. Dultagravil (DTG) based treatment has highly potent antiviral activity, a high genetic barrier to resistance, and a high safety profile. But, the effect of DTG on viral suppression in children and adolescents is not understood in Ethiopian context.
Objective: To assess the HIV viral load suppression status and associated factors among children and adolescents on DTG based Anti-Retroviral (AR) regimen, Addis Ababa –Ethiopia.
Methods: We employed a health facility based cross-sectional study design on children and adolescents receiving dolutegravir based ART regimen for at least 12 months. Stratified sampling technique was employed to get 430 samples. Binary logistic regression model was carried out to identify predictors associate with viral load suppression. Model fitness was checked using Hosmer and Lemeshow test for goodness of fit. Odds ratio with a 95% confidence level was used to measure the strength of association. Variables with p <0.05 were considered statistically significant.
Result: Out of 430 participants, 428 (97.2%) responded. The proportion of viral suppression was 89.1%. During bivariate analysis , Age, Educational level, Orphanage status, relation, Line of regimen, Anxiety , MDD, Stigma , Base line WHO staging, Nutritional status, using Reminder, previous viral load suppression, adherence were significantly associated with viral load suppression at p value 0.25. However, during multivariate analysis, Adherence,(AOR=3.832, (CI:1.489,9.86)), previous viral suppression status (AOR= 3.051, (CI:1.35,6.89)), caring by parents (AOR= 3.30, CI:1.44, 9.56), nutritional status (AOR=3.65, (CI:1.356,9.634), line of regime (AOR=0.21, (CI:0.06,0.67)), educational level ( (AOR=0.208; (CI:0.057,0.762), were significantly associated with viral suppression.
Conclusion: Dalutagravir based regimen maintains high viral suppression rate and improves medication adherence significantly compared to previous regimen. Implementing effective mechanism to enhance adherence among children and adolescents is very crucial.
References
The path that ends AIDS: UNAIDS Global AIDS Update 2023 [Internet]. Available from: http://www.wipo.int/amc/en/mediation/rules.
UNAIDS, UNAIDS Global AIDS update. The path that ends AIDS. 2023;80–2. Available from: http://www.wipo.int/amc/en/mediation/rules.
Ethiopian Public Health Institute. HIV Related Estimates and Projections in Ethiopia for the Year 2021-2022 August 2022 Addis Ababa. Gmf [Internet]. 2023;(May):1–32. Available from: https://ephi.gov.et/wp-content/uploads/2021/02/HIV-Estimates-and-projection-for-the-year-2022-and-2023.pdf
PEPFAR. Ethiopia Country Operational Plan (COP) 2015 Strategic Direction Summary. 2015;1–51. Available from: https://www.pepfar.gov/documents/organization/250287.pdf.
Snapshot G. 2023 Global Snapshot on HIV and AIDS Progress and priorities for children , adolescents and pregnant women 2023 Global Snapshot on HIV and AIDS Where we are now. 2023.
Tafere GW, Hunduma F, Yesuf A. Viral suppression rate at operation triple zero (Otz) and regular art follow-Up programs and associated factors among adolescent clients of Addis Ababa Ethiopia: a comparative cross-sectional study. Virol J. 2023 Dec 1;20(1).
Bitwale NZ, Mnzava DP, Kimaro FD, Jacob T, Mpondo BCT, Jumanne S. Prevalence and Factors Associated with Virological Treatment Failure among Children and Adolescents on Antiretroviral Therapy Attending HIV/AIDS Care and Treatment Clinics in Dodoma Municipality, Central Tanzania. J Pediatric Infect Dis Soc. 2021;10(2):131–40.
Moore CL, Turkova A, Mujuru H, Kekitiinwa A, Lugemwa A, Kityo CM, et al. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based doluteg. BMC Infect Dis. 2021;21(1):1–14.
FMoH. Implementation manual for DTG rollout and ART optimization in Ethiopia. 2019; (January):56.
Khamadi SA, Bahemana E, Dear N, Mavere C, George F, Kapene R, et al. Factors Associated With Viral Suppression and Drug Resistance in Children and Adolescents Living With HIV in Care and Treatment Programs in Southern Tanzania. J Pediatric Infect Dis Soc. 2023;12(6):353–63.
The role of HIV viral suppression in improving individual health and reducing transmission: policy brief. Geneva: World Health Organization; 2023.
Singh JA, Siddiqi M, Parameshwar P, Chandra-Mouli V. World Health Organization Guidance on Ethical Considerations in Planning and Reviewing Research Studies on Sexual and Reproductive Health in Adolescents. J Adolesc Heal [Internet]. 2019;64(4):427–9. Available from: https://doi.org/10.1016/j.jadohealth.2019.01.008.
Akinwande MO, Dikko HG, Samson A. Variance Inflation Factor: As a Condition for the Inclusion of Suppressor Variable(s) in Regression Analysis. Open J Stat. 2015;05(07):754–67.
Djiyou ABD, Penda CI, Madec Y, Ngondi GD, Moukoko A, Varloteaux M, et al. Viral load suppression in HIV-infected adolescents in cameroon: towards achieving the UNAIDS 95% viral suppression target. BMC Pediatr. 2023;23(1):1–8.
Gn R, Kc N, Tp A, Pm U, Og O, Onyemocho A. The effectiveness of dolutegravir among HIV Positive adolescents attending ART clinic at Benue State University Teaching Hospital, Makurdi, Benue State, Nigeria, Jos Journal of Medicine, 2023, 16(1):46–53.
Kingwara L, Inzaule SC, Momanyi L, Jordan MR, Nyanya W, Bowen N, et al. Impact of nucleos(t)ide reverse transcriptase inhibitor resistance on dolutegravir and protease-inhibitor-based regimens in children and adolescents in Kenya. Aids. 2022;36(4):611–3.
Maghembe AA, Boer MS de, Marikias G, Amour C, Mahande MJ. HIV Viral Suppression and Associated Factors Among Children and Adolescents on a Dolutegravir based Antiretroviral Regimen in Tanzania Mainland. medRxiv [Internet]. 2023;2023.05.17.23290106. Available from: http://medrxiv.org/content/early/2023/05/25/2023.05.17.23290106.abstract.
Egbonrelu N, Olugbusi J. Factors Associated with Poor Viral Suppression Among Children and Adolescents Accessing Antiretroviral Therapy in Selected Health Facilities in Lagos, Nigeria. Res Sq. 2021;11(6):58–75.
Kouamou V, Machekano R, Mapangisana T, Maposhere C, Munyati S, Mutsvangwa J, et al. Tenofovir, Lamivudine, and Dolutegravir Among Rural Adolescents in Zimbabwe: A Cautionary Tale. AIDS Res Hum Retroviruses. 2022;38(10):774–8.
Fenta DA, Wube TB, Nuru MM. Long-Term Immunological and Virological Outcomes in Children Receiving Highly Active Antiretroviral Therapy at Hawassa University College of Medicine and Health Sciences, Southern Ethiopia. J Immunol Res. 2021;2021.
Tsikhutsu I, Bii M, Dear N, Ganesan K, Kasembeli A, Sing’Oei V, et al. Prevalence and Correlates of Viral Load Suppression and Human Immunodeficiency Virus (HIV) Drug Resistance among Children and Adolescents in South Rift Valley and Kisumu, Kenya. Clin Infect Dis. 2022;75(6):936–44.
Diress G, Dagne S, Alemnew B, Adane S, Addisu A. Viral Load Suppression after Enhanced Adherence Counseling and Its Predictors among High Viral Load HIV Seropositive People in North Wollo Zone Public Hospitals, Northeast Ethiopia, 2019: Retrospective Cohort Study. AIDS Res Treat. 2020;2020.
